GlassScriptPhysician profile
Eric W Bradburn
NPI 1972559714
$3,930.85
in general payments reported to CMS, 2019-2025
37 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $443 · 2021: $201 · 2022: $477 · 2023: $1,109 · 2024: $783 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468 · Education: $8.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.76 |
| Education | $8.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $354.50 | 2020-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $319.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $283.07 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.91 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $251.89 | 2020-2024 | Nucala, Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $223.45 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $222.89 | 2020-2025 | Airsupra, Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $202.62 | 2024 | |
| Sanofi-Aventis U.S. LLC | $201.81 | 2019-2025 | |
| Allergan, INC. | $190.30 | 2020 | |
| Pfizer INC. | $168.89 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.16 | 2022 | |
| Lilly USA, LLC | $145.08 | 2022-2025 | Jardiance, Zepbound, Kisunla |
| Supernus Pharmaceuticals, INC. | $143.13 | 2019-2020 | |
| Esperion Therapeutics, INC. | $119.70 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bradburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.